Exane ups Rovi to 'outperform', updates mid-cap top picks
** Exane BNP Paribasupgrades Spanish pharma group Rovi ROVI.MC to "outperform" from "neutral" and updates its mid-cap top picks, with Colonial COL.MC making the list while Merlin Properties MRL.MC dropping out
** The broker says it is more optimistic on Rovi than the market even after the warning on the company's dependence on Moderna
** At the current share price of 74.4 euros, Exane still sees upside potential of more than 20%, even excluding benefitsfrom a potential deal on its manufacturing business
** In Spain's real estate, Exane prefers Colonial to Merlin as the complexity of the latter's data center project and its lower discount to net asset value make it less attractive
** Among glass makers, it believes that France's Verallia VRLA.PA earnings will not likely see a turnaround in Q3, while Spain's Vidrala VID.MC has higher visibility in the UK and Brazil, although says the latter trades at a slight premium
** The brokerage does not see major recovery in H2 for the pool equipment maker Fluidra FLUI.MC after Q2 warnings from U.S. sector's players on lower new builds
Reporting by Matteo Allievi
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
